bioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer Screening
bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer and lung disease, today announced the expansion of its partnership with the American Cancer Society (ACS) to raise funding for ACS’ Lung Quality Improvement (QI) initiative to increase the rate of lung cancer screening.
- bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer and lung disease, today announced the expansion of its partnership with the American Cancer Society (ACS) to raise funding for ACS’ Lung Quality Improvement (QI) initiative to increase the rate of lung cancer screening.
- Initially launched in November 2023 to support local lung cancer screening, bioAffinity Technologies and its ACS South Region partner have expanded the geographic reach to include ACS Lung QI sites across the country.
- The campaign highlights the value of early screening and provides information about bioAffinity Technologies’ CyPath® Lung , a noninvasive test to improve early detection of lung cancer.
- The ACS website has an interactive map that helps people eligible for screening find a cancer screening location near them.